Tyber Medical LLC, an orthopedic device manufacturer based in Bethlehem, Pennsylvania, has acquired 100 percent of the capital of ADSM-Synchro Medical, an orthopedic medical device company based in France.
Tyber Medical Acquires French Orthopedic Medical Device Company
2 min read Premium comments
#tybermedicalSecondary#adsm#synchromedical
ADSM creates and distributes implants for the surgical treatment of forefoot pathologies. Its product portfolio includes the “ToeGrip® Classic, the first hammer toe implant of its kind developed with PEEK material.” Its other products include the EXray®20 and the EXray®30, which, according to the company, is the “worldwide first Peek forefoot screw system.” Its product portfolio also includes the TigerTrack® forefoot screw system. ADSM’s product portfolio will be integrated into Tyber Medical’s private label spine, extremity, and trauma portfolio.
Tyber Medical Chief Commercial Officer James Abraham said, “The addition of ADSM’s product lines to our portfolio will create new avenues of growth within our overall product offering for our OEM [original equipment manufacturer] partners.”
Abraham continued, “The wealth of expertise and product innovation delivered by the ADSM team, extends our international market opportunity with our OEM customers and greatly accelerates our MDR product approval strategy.”
The acquisition of ADSM expands Tyber Medical’s presence abroad. According to Tyber, the acquisition will bring to the company, “a wider range of product options in the MIS bunion, PEEK hammertoe and screw fixation arenas.”
In addition to expanding Tyber Medical’s portfolio, the acquisition will also add “another EU notified body, providing multiple pathways to accelerate certification of Tyber Medical’s full product portfolio under Europe’s new Medical Device Regulation (MDR).”
Tyber Medical Chief Executive Officer Jeff Tyber said, “ADSM’s strong experience and existing Class I, Class IIa and Class IIb MDR approval of their screw-based technology is key to accelerating our global market access strategy.”
“What initially attracted Tyber Medial to ADSM was their complementary products that enable us to fill potential gaps in our customers’ product portfolios with our rapid-access private label model,” Damien Sibilla, Tyber Medical Chief Financial Officer told OTW. “We were also impressed with ADSM’s experience navigating the MDR approval process, giving us an additional accelerated pathway for product clearance in Europe.”
ADSM Founder and President Luigi Bivi will remain with the company as president. In that role he will continue to support ADSM as well as support the growth of Tyber Medical in Europe. Bivi has extensive knowledge of the European market and was formerly the vice president of sales for Smith & Nephew Europe.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.